Publications

Lab members in bold.

Ruiz de Galarreta M, Lujambio A. DNA sensing in senescence. Nat Cell Biol. 2017 Aug 31;19(9):1008-1009. doi: 10.1038/ncb3603.

Deshmukh M, Nakagawa S, Higashi T, Vincek A, Venkatesh A, Ruiz de Galarreta M, Koh AP, Goossens N, Hirschfield H, Bian CB, Fujiwara N, Ono A, Hoshida H, El-Abtah M, Ahmad NB, Lujambio A, Sanchez R, Fuchs BC, Poelstra K, Prakash J, Hoshida Y; Precision Liver Cancer Prevention Consortium. Cell type-specific pharmacological kinase inhibition for cancer chemoprevention. Nanomedicine. 2017 Nov 20;14(2):317-325. doi: 10.1016/j.nano.2017.11.004.

Ruiz de Galarreta M, Lujambio A. Therapeutic editing of hepatocyte genome in vivo. J Hepatol. 2017 Oct;67(4):818-828. doi: 10.1016/j.jhep.2017.05.012.

Molina-Sánchez P, Lujambio A. Strategies for HCC target discovery. Aging (Albany NY). 2017 Apr;9(4):1088-1089. doi: 10.18632/aging.101233.

Rapisarda V, Borghesan M, Miguela V, Encheva V, Snijders AP, Lujambio A, O’Loghlen A. Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway. Cell Rep. 2017 Mar 7;18(10):2480-2493. doi: 10.1016/j.celrep.2017.02.012.

Valerio DG, Xu H, Chen CW, Hoshii T, Eisold ME, Delaney C, Cusan M, Deshpande AJ, Huang CH, Lujambio A, Zheng YG, Zuber J, Pandita TK, Lowe SW, Armstrong SA. Histone Acetyltransferase Activity of MOF Is Required for MLL-AF9 Leukemogenesis. Cancer Res. 2017 Feb 15. doi: 10.1158/0008-5472.CAN-16-2374. [Epub ahead of print]

Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Iglesias D, Webb TR, Lowe SW, López-Otín C, Freije JM. USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. J Biol Chem. 2017 Mar 10;292(10):4164-4175. doi: 10.1074/jbc.M116.762757. Epub 2017 Feb 1.

Miguela V, Lujambio A. Uncovering the role of USP54 in cancer. Oncotarget. 2017 Jan 26. doi: 10.18632/oncotarget.14820. [Epub ahead of print]

Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, Tovar V, Sia D, Molina-Sanchez P, Nguyen C, Nakagawa S, Llovet JM, Hoshida Y, Lujambio A. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumor growth in preclinical models of hepatocellular carcinoma. In press in Gut (2016).

Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. IGF2 is up-regulated by epigenetic mechanisms in hepatocellular carcinoma and is an actionable oncogene in experimental models. S0016-5085. Gastroenterology (2016).

Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu BX, Zhang C, Bollag G, de Stanchina E, Herlyn M, Lujambio A, Gavathiotis E, Poulikakos PI. An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell. S1535-6108(16)30284-7 (2016).

Manchado E, Weissmueller S, Morris JP IV, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran FB, Engelman A, Rudin CM, Rosen N, Lowe SW. A combinatorial strategy for treating KRAS mutant lung cancer. Nature. 30;534(7609):647-51 (2016).

Lujambio A. To clear or not to clear (senescent cells)? That is the question. Bioessays S56-64 (2016).

Lujambio A, Villanueva A. The usual SASPects of liver cancer. Aging. 7(6):348-349 (2015)

Vidal SJ, Rodriguez-Bravo V, Quinn SA, Lujambio A, Rodriguez-Barrueco R, Hoshida Y, Petrylak DP, Rabadan R, Silva J, Lowe SW, Cordon-Cardo C, Domingo-Domenech J. Therapeutic targeting of a GATA2-IGF2 axis in lethal prostate cancer. Cancer Cell. 27(2):223-39 (2015).

Huang CH*, Lujambio A*, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes & Development 28:1800-1814 (2014). * equal contribution.

Elizalde M, Urtasun R, Azkona M, Latasa MU, Goñi S, García-Irigoyen O, Uriarte I, Segura V, Collantes M, Di Scala M, Lujambio A, Prieto J, Ávila MA, Berasain C. Slu7 is an essential factor for the preservation of liver differentiation, metabolic function and quiescence. Journal of Clinical Investigation 124(7):2909-20 (2014).

Lujambio A, Akkari L, Simon J, Grace D, Tschaharganeh DF, Bolden JE, Zhao Z, Thapar V, Joyce JA, Krizhanovsky V, Lowe SW. Non-cell-autonomous tumor suppression by p53Cell 153(2):449-60 (2013).

Carmona FJ, Villanueva A, Vidal A, Muñoz C, Puertas S, Penin RM, Gomà M, Lujambio A, Piulats JM, Mesía R, Sánchez-Céspedes M, Manós M, Condom E, Eccles SA, Esteller M. Epigenetic Disruption of Cadherin-11 in Human Cancer Metastasis. J Pathol. doi: 10.1002/path.4011 (2012).

Lujambio A, Lowe SW. The microcosmos of cancer. Nature 15;482(7385):347-55 (2012).

Iliou MS, Lujambio A, Portela A, Brüstle O, Koch P, Andersson-Vincent PH, Sundström E, Hovatta O, Esteller M. Bivalent histone modifications in stem cells poise miRNA loci for CpG island hypermethylation in human cancer. Epigenetics 1;6(11) (2011).

Vegliante MC, Royo C, Palomero J, Salaverria I, Balint B, Martín-Guerrero I, Agirre X, Lujambio A, Richter J, Xargay-Torrent S, Bea S, Hernandez L, Enjuanes A, Calasanz MJ, Rosenwald A, Ott G, Roman-Gomez J, Prosper F, Esteller M, Jares P, Siebert R, Campo E, Martín-Subero JI, Amador V. Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. PLoS One 6(6):e21382 (2011).

Lujambio A, Portela A, Liz J, Melo SA, Rossi S, Spizzo R, Croce CM, Calin GA, Esteller M. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 29(48):6390-6401 (2010).

Fernandez AF, Rosales C, Lopez-Nieva P, Grana O, Ballestar E, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, Pino I, Javierre B, Carmona FJ, Acquadro F, Steenbergen RD, Snijders PJ, Meijer CJ, Pineau P, Dejean A, Lloveras B, Capella G, Quer J, Buti M, Esteban JI, Allende H, Rodriguez-Frias F, Castellsague X, Minarovits J, Ponce J, Capello D, Gaidano G, Cigudosa JC, Gomez-Lopez G, Pisano DG, Valencia A, Piris MA, Bosch FX, Cahir-McFarland E, Kieff E, Esteller M. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19(3):438-451 (2009).

Lujambio A, Esteller M. How epigenetics can explain human metastasis: A new role for microRNAs. Cell Cycle 8(3): 377-382 (2009).

Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 105(36): 13556-13561 (2008).

Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, Lecanda F, Montuenga LM. Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 9(10): 840-852 (2007).

Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6(12): 1455-1459 (2007).

Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S, Suarez-Gauthier A, Sanchez-Cespedes M, Git A, Spiteri I, Das PP, Caldas C, Miska E, Esteller M. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 67(4): 1424-1429 (2007).